Dhavalkumar Patel, MD, PhD, is Executive Vice President and Chief Scientific Officer of Sana Biotechnology.

Prior to joining Sana in 2024, Dhaval served as Executive Vice President and Chief Scientific Officer of UCB, a multinational biopharmaceutical company headquartered in Brussels, Belgium, where he and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®) and zilucoplan (Zilbrysq®). Prior to UCB, he spent 10 years at Novartis, most recently as the Head of Research of the Novartis Institutes for BioMedical Research (NIBR) Europe. During his tenure, he led research in the autoimmune, transplantation, and inflammation disease areas, contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dhaval served as a member of the Board of Directors of Inflazome Ltd. prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Anokion SA, Priothera Ltd., and Quell Therapeutics Limited and serves as Chair of the Board of Directors for Mimetas BV.

Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board certified in internal medicine, rheumatology, and allergy & immunology.